Literature DB >> 2684299

Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay.

I Doxiadis1, U Westhoff, H Grosse-Wilde.   

Abstract

A simplified enzyme linked immunosorbent assay utilizing an HLA class I framework-specific monoclonal antibody and a polyclonal enzyme linked beta-2 microglobulin specific antiserum has been established for the quantitative measurement of soluble HLA class I molecules. A total of 219 unrelated healthy individuals and 137 members of 28 families typed for HLA were analyzed for their non-membrane bound, i.e. soluble HLA-A,B,C antigens (sHLA-A,B,C). As reported by others, we observed associations of higher or lower sHLA-A,B,C values to particular HLA antigens: High plasma values were observed in probands positive for HLA-A23, A24, A29, Aw33, Bw65, and Cw8 and low values in HLA-B27 and B37 positive individuals. However, as shown by family studies, levels of sHLA-A,B,C were apparently not controlled by the MHC haplotypes alone, since no significant difference between HLA identical siblings and two haplotype different individuals could be detected. Thus, additional non-MHC linked gene(s) may be involved in the release of class I gene products.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684299     DOI: 10.1007/bf00349066

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  25 in total

1.  Anti-HLA-B7,B27,Bw42,Bw54,Bw55,Bw56, Bw67,Bw73 monoclonal antibodies: specificity, idiotypes, and application for a double determinant immunoassay.

Authors:  K Sakaguchi; R Ono; M Tsujisaki; P Richiardi; A Carbonara; M S Park; R Tonai; P I Terasaki; S Ferrone
Journal:  Hum Immunol       Date:  1988-03       Impact factor: 2.850

2.  Histocompatibility antigens of human plasma. Localization to the HLD-3 lipoprotein fraction.

Authors:  R H Aster; B H Miskovich; G E Rodey
Journal:  Transplantation       Date:  1973-09       Impact factor: 4.939

3.  Soluble HL-A7 antigen: localization in the beta-lipoprotein fraction of human serum.

Authors:  R K Charlton; C M Zmijewski
Journal:  Science       Date:  1970-11-06       Impact factor: 47.728

4.  Immunogenicity of serum HLA antigens in allogeneic combinations.

Authors:  M A Pellegrino; F Indiveri; U Fagiolo; A Antonello; S Ferrone
Journal:  Transplantation       Date:  1982-05       Impact factor: 4.939

5.  HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties.

Authors:  R A Reisfeld; J P Allison; S Ferrone; M A Pellegrino; M D Poulik
Journal:  Transplant Proc       Date:  1976-06       Impact factor: 1.066

6.  Distribution of 'free' and HLA-associated human beta 2-microglobulin in some plasma membranes and biological fluids.

Authors:  T Plesner; O J Bjerrum
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

7.  Two forms of HLA class I molecules in human plasma.

Authors:  M S Krangel
Journal:  Hum Immunol       Date:  1987-10       Impact factor: 2.850

8.  Biochemical complexity of serum HLA class I molecules.

Authors:  L M Dobbe; N J Stam; J J Neefjes; M J Giphart
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

9.  A double determinant immunoassay for HLA class I typing using serum as an antigen source.

Authors:  C Russo; M Fotino; A Carbonara; S Ferrone
Journal:  Hum Immunol       Date:  1987-05       Impact factor: 2.850

10.  Expression of HLA-B12 on platelets, on lymphocytes and in serum: a quantitative study.

Authors:  M Liebert; R H Aster
Journal:  Tissue Antigens       Date:  1977-04
View more
  8 in total

Review 1.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

2.  HLA-B27 determination using serological methods. A comparison of enzyme immunoassay and a microlymphocytotoxic test with flow cytometry and a molecular biological assay.

Authors:  A Dunky; J Neumüller; C Hübner; G F Fischer; P M Bayer; E Wagner; D W Schwartz; W R Mayr
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  Detection of HLA class I-specific antibodies by the QuikScreen enzyme-linked immunosorbent assay.

Authors:  D P Lucas; M L Paparounis; L Myers; J M Hart; A A Zachary
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

4.  Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?

Authors:  F Puppo; A Picciotto; S Brenci; G Varagona; M Scudeletti; M Ghio; V Balestra; G Celle; F Indiveri
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

5.  Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).

Authors:  W E Aulitzky; H Grosse-Wilde; U Westhoff; H Tilg; W Aulitzky; G Gastl; M Herold; C Huber
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.

Authors:  M Ritter; C Huber; J Auböck; H Pohl-Markl; J Troppmair; M Herold; A Gächter; W Nussbaumer; G Böck; D Nachbaur
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

7.  Detection in chick embryo of fetoproteins not recognized by the dam's immune system and of soluble alloantigens. Presumptive teratogenic and abortogenic capacity of their specific IgY.

Authors:  Antonio Rodríguez-Burgos
Journal:  BMC Immunol       Date:  2003-06-27       Impact factor: 3.615

8.  HLA-G UTR haplotype conservation in the Malian population: association with soluble HLA-G.

Authors:  Federico Carlini; Karim Traore; Nissem Cherouat; Pierre Roubertoux; Stéphane Buhler; Martì Cortey; Sophie Simon; Ogobara Doumbo; Jacques Chiaroni; Christophe Picard; Julie Di Cristofaro
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.